You are on the TAC legacy website. Please visit our new website: www.tac.org.za

TAC complaint against MSD

warning: Creating default object from empty value in /usr/www/users/tacaor/public_site/community/modules/taxonomy/taxonomy.pages.inc on line 34.
Printer-friendly version

TAC complaint increases access to efavirenz: MSD finally agrees to grant licenses on reasonable terms

Acting on behalf of TAC, the AIDS Law Project (ALP) lodged a complaint with the Competition Commission of South Africa in late 2007 alleging that MSD (Pty) Ltd – the South African subsidiary of multinational drug company Merck – was unlawfully refusing to license the antiretroviral (ARV) medicine efavirenz (EFV) on reasonable terms. (“TAC complains to the Competition Commission about the anti-competitive conduct of the world's largest pharmaceutical company” at http://www.tac.org.za/community/node/2127.) Today, TAC is pleased to announce that MSD is no longer acting in an anticompetitive way, paving the way for the market entry of a wide range of affordable EFV products.

Also read our updated fact sheet on the complaint.

Syndicate content